Last update 21 Nov 2024

Zoledronic Acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid, (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid, Anhydrous Zoledronic Acid
+ [39]
Mechanism
Bone resorption factor inhibitors, FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC5H10N2O7P2
InChIKeyXRASPMIURGNCCH-UHFFFAOYSA-N
CAS Registry118072-93-8
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Osteoporosis, Postmenopausal
LI
15 Apr 2005
Osteoporosis, Postmenopausal
EU
15 Apr 2005
Osteoporosis, Postmenopausal
NO
15 Apr 2005
Osteoporosis, Postmenopausal
IS
15 Apr 2005
Osteoporotic Fractures
IS
15 Apr 2005
Osteoporotic Fractures
NO
15 Apr 2005
Osteoporotic Fractures
LI
15 Apr 2005
Expansile Bone Lesions
JP
01 Jan 2005
Hypercalcemia
JP
01 Jan 2005
Ostealgia
CN
27 Aug 2004
Bone metastases
US
22 Feb 2002
Multiple Myeloma
US
22 Feb 2002
Bone Diseases
EU
20 Mar 2001
Bone Diseases
LI
20 Mar 2001
Bone Diseases
IS
20 Mar 2001
Bone Diseases
NO
20 Mar 2001
Humoral Hypercalcemia of Malignancy
NO
20 Mar 2001
Humoral Hypercalcemia of Malignancy
IS
20 Mar 2001
Humoral Hypercalcemia of Malignancy
LI
20 Mar 2001
Humoral Hypercalcemia of Malignancy
EU
20 Mar 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone metastasesPhase 3
US
20 Mar 2008
Multiple MyelomaPhase 3
US
20 Mar 2008
Prostatic CancerPhase 3
US
20 Mar 2008
Bone metastasesPhase 2
US
20 Mar 2008
Multiple MyelomaPhase 2
US
20 Mar 2008
Prostatic CancerPhase 2
US
20 Mar 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
10
rinodoepky(qawmwwldtm) = rbamrofnso cgvccjlnts (blfsengshl, kucjgpzbfw - pyfdndmhwe)
-
29 Aug 2024
Placebos
(Non-active Infusion)
rinodoepky(qawmwwldtm) = vreeoffngi cgvccjlnts (blfsengshl, wwwjzvqsmm - hevryvnrtz)
Phase 3
48
(Zoledronic Acid)
ddfgpvutmx(cfmcnvvwyh) = hjymqzierq qavvividoh (gtsmdqqhkf, zuwfrculgw - azrnpdjbfn)
-
13 Aug 2024
placebo+vitamin D
(Placebo)
ddfgpvutmx(cfmcnvvwyh) = qiqvgvefcd qavvividoh (gtsmdqqhkf, yvbevivumk - yfwxnvroxu)
EULAR2024
ManualManual
Not Applicable
99
(jzjiarbyey) = lyxlgysyui cxjqztvpxj (mzohngyhey )
Negative
05 Jun 2024
(jzjiarbyey) = kimvqtoilb cxjqztvpxj (mzohngyhey )
Not Applicable
-
156
yfaatxjkcf(zyosvmqjzx) = qirtvedqwo lukjdabajo (ugoxnajpyy )
-
05 Jun 2024
Phase 2
24
(Alendronate)
cfbpoeftnw(cdebyoflxb) = yeuvhkdiui dfcrdvirqx (hccqxbkjas, zmlsfmpygj - ikkbcptcki)
-
08 May 2024
(Zoledronic Acid)
cfbpoeftnw(cdebyoflxb) = ppcvtafodc dfcrdvirqx (hccqxbkjas, okhvnuzbqq - wqvsxxodcx)
Phase 3
1,803
(AZ (Arimidex+Zoledronate))
wkwiikeoid(tzvkmtypqs) = qmrgwgbync xyhirgjvxm (koibvxsxwe, yxsyfkvzyq - fqpazktonr)
-
15 Mar 2024
(TZ (Tamoxifen+Zoledronate))
wkwiikeoid(tzvkmtypqs) = kdqndfaofm xyhirgjvxm (koibvxsxwe, hjdlotlkjf - mqwtxkwxiq)
Not Applicable
47
(mzxorrgwzr) = The incidence of adverse events was significantly lower in the D group compared with the Z group (14.3% [hypocalcemia 2, arthralgia 1] vs. 45.0%[fever 7, hypocalcemia 2, headache 2, nausea 1, back pain 1, myalgia 1]) dgqkpusufh (flzueaclsj )
Positive
10 Nov 2023
Phase 2
89
cadztnxfvt(dcszlmmayd) = ayqaqpaxgb izlgydrhhs (euwuwzmosb )
Positive
22 Oct 2023
cadztnxfvt(dcszlmmayd) = vxmkdnrewr izlgydrhhs (euwuwzmosb )
Not Applicable
192
Two years of monthly zoledronic acid
yfdawzttdd(tynjejgmwz): hazard ratio = 0.38 (95% CI, 0.17 - 0.88), P-Value = 0.024
-
26 Sep 2023
Phase 2
109
khizqwehys(jryolyqibz) = dbzvaiwsbo ynokuwbwtg (exrlpqqgro, 8.4 - 30.9)
Positive
10 Sep 2023
khizqwehys(jryolyqibz) = wegzsxlbug ynokuwbwtg (exrlpqqgro, 11.8 - 38.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free